FDA Approved: SEREVENT DISKUS — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for SEREVENT DISKUS (salmeterol xinafoate) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SEREVENT DISKUS (SALMETEROL XINAFOATE)

Snippet

SUPPL AP for SEREVENT DISKUS (SALMETEROL XINAFOATE)